Hikma Gets More Time On Vascepa Response As Amarin CEO Exits
ANDA Sponsor Argued Unsuccessfully For A 45-Day Extension
Hikma has won more time to respond to Amarin’s certiorari petition to the US Supreme Court over a Federal Circuit decision invalidating Vascepa intellectual property – but not the 45 days the company was looking for. Meanwhile, Amarin’s CEO John Thero is to stand down later this year.
